Cargando…

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies

Detalles Bibliográficos
Autores principales:	Evans, MC, Paquet, A, Phung, P, Parikh, A, Petropoulos, C, Wrin, T, Haddad, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3442070/ http://dx.doi.org/10.1186/1742-4690-9-S2-P353

Ejemplares similares

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method
por: Evans, Mark C, et al.
Publicado: (2014)

Mapping epitopes on CRF01_AE viruses recognized by broadly neutralizing antibodies in sera from elite neutralizers from North America and Thailand
por: O'Rourke, SM, et al.
Publicado: (2012)

P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)

Mutations in the V1 domain of Thai CRF01-AE viruses that confer sensitivity/resistance to broadly neutralizing antibodies
por: O'Rourke, S, et al.
Publicado: (2012)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

P04-51 LB. The epitopes of two newly identified broad and potent neutralizing antibodies, PG9 and PG16
por: Walker, L, et al.
Publicado: (2009)

Broad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamas
por: McCoy, LE, et al.
Publicado: (2012)

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection
por: Schweighardt, B, et al.
Publicado: (2009)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Broad neutralization coverage of HIV by multiple highly potent antibodies
por: Walker, Laura M., et al.
Publicado: (2011)

S021-06 OA. Potent and broad neutralizing antibodies from HIV-1 non-clade B infected donor reveal a new HIV-1 vaccine target
por: Phogat, SK, et al.
Publicado: (2009)

Structural definition of a novel CD4-induced epitope that is targeted by a single-headed immunoglobulin to effect broad and potent HIV neutralization
por: Acharya, P, et al.
Publicado: (2012)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies
por: Wiehe, K, et al.
Publicado: (2009)

Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120
por: Zhou, T, et al.
Publicado: (2012)

P19-03. Molecular mechanisms for enhancing the antigenicity of the carbohydrate epitope of the broadly neutralizing anti-HIV-1 antibody 2G12
por: Fulton, Z, et al.
Publicado: (2009)

P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors
por: Binley, J, et al.
Publicado: (2009)

Systemic administration of a broadly-neutralizing IgG antibody to generate HIV-neutralization responses in breast milk
por: Fouda, GG, et al.
Publicado: (2012)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Isolation of broadly neutralizing HIV-1 antibodies from high-throughput single B cell culture
por: Longo, NS, et al.
Publicado: (2012)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

A broad and potent neutralization epitope in SARS-related coronaviruses
por: Yuan, Meng, et al.
Publicado: (2022)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

P04-43. Neutralizing antibody responses against conformational envelope epitopes in early HIV-1 infection
por: Bar, KJ, et al.
Publicado: (2009)

P05-03. The use of immune complexes to enhance antibody responses against neutralizing epitopes on HIV envelope
por: Hioe, CE, et al.
Publicado: (2009)

Construction of SHIVs expressing quaternary neutralization epitopes in Env and mimicking the neutralization phenotype of typical HIV-1 isolates
por: Theis, JF, et al.
Publicado: (2012)

P05-09. 4e10 epitope-scaffolds mimic the antibody-bound epitope conformation and block neutralization by sera from rare HIV+ individuals
por: Ban, YA, et al.
Publicado: (2009)

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

Construction and characterization of neutralizing antibody fragments for efficient access to V3 epitope
por: Maruta, Y
Publicado: (2012)

Characterization of V1/V2-specific antibodies present in broadly neutralizing plasma isolated from HIV-1 infected individuals
por: Krachmarov, C, et al.
Publicado: (2012)

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
por: Schoofs, Till, et al.
Publicado: (2019)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies
por: Visciano, M, et al.
Publicado: (2009)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

P05-13. Fragments of HIV-1 gp41 derivatives presented on virus-like particles with preserved binding affinity for broadly neutralizing antibodies
por: Benen, T, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

1231. VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness
por: Pizzuto, Matteo Samuele, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lpj85ocfhsd1unvh4seq2r6c7r